Skip to main content
SpringerLink
Log in

Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The aim of the present investigation was to prepare and evaluate the influence of adding fines on the in vitro performance of liposomal amikacin dry powder inhaler (AMK LDPI) formulations. Liposomes composed of hydrogenated soyaphosphatidylcholine, cholesterol and saturated soyaphosphatidylglycerol (AMK 1), or stearylamine (AMK 2) were prepared by a reverse phase evaporation technique, extruded to reduce size and separated from unentrapped drug. Purified liposomal dispersion was subjected to lyophilization using optimized cryoprotectant to achieve maximum percentage drug retentio (PDR). Lactose carrier in varying mass ratios with or without addition of fines in different mixing sequences was used to formulate AMK LDPI formulations. AMK LDPI formulations were characterized for angle of repose, compressibility index, dispersibility index, scanning electron microscopy, and fine perticle fraction (FPF). PDR was found to be 97.6%±2.2% for AMK1 and 98.5%±1.9% for AMK2 using sucrose as optimized cryoprotectant in lipid:sucrose ratio of 1∶4. Lactose carrier containing 10% fines (wt/wt) was found to be the optimum blend at 1∶5 mass ratio of liposome:lactose. The addition of fines and the order of mixing of fines were found to influence the FPF with significantly different device fractions. FPF of AMK LDPI formulations using Rotahaler as the delivery device at 30, 60, and 90 L/min were found to be 21.85%±2.2% and 24.6%±2.4%, 25.9% ±1.8% and 29.2%±2.1%, and 29.5%±2.6% and 34.2%±2.0% for AMK1 and AMK2, respectively. From the studies performed in this investigation, it was observed that liposomal charge, addition of fines and order of mixing fines, has a significant effect (P<.05) on in vitro deposition of drug from LDPI formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy, selection, administration and monitoring.Drugs. 1994;47:902–913.

    Article  CAS  Google Scholar 

  2. Molitoris BA. Cell biology of aminoglycoside nephrotoxicity: newer aspects.Curr Opin Nephrol Hypertens. 1997;6:384–388.

    CAS  Google Scholar 

  3. Senior J. Fate and behavior of liposomes in vivo.Crit Rev Ther Drug Carrier Syst. 1987;3:123–193.

    CAS  Google Scholar 

  4. Patel HM. Serum opsonins and liposomes: their interaction and opsonophagocytosis.Crit Rev Ther Drug Carrier Syst. 1992;15:57–88.

    Google Scholar 

  5. Ganderton D. The generation of respirable cloud from coarse powder aggregates.J Biopharm Sci. 1992;3:101–105.

    Google Scholar 

  6. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation.J Aerosol Sci. 1996;27:769–783.

    Article  Google Scholar 

  7. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in vitro deposition.Int J Pharm. 1997;154:31–37.

    Article  CAS  Google Scholar 

  8. Staniforth JN. Improvement in dry powder inhaler performance: surface passivation effects. In:Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK; 1996:86–89.

    Google Scholar 

  9. Zeng XM, Tee SK, Martin GP, Marriott C. Effect of mixing procedure and particle size distribution of carrier particles on the deposition of salbutamol sulphate from dry powder inhaler formulations. In:Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK; 1996:40–43.

    Google Scholar 

  10. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.Pharm Res. 1998;15:562–569.

    Article  CAS  Google Scholar 

  11. Kim JC, Kim JD. Preparation by spray drying of amphotericin B-phospholipid composite particles and their anticellular activity.Drug Deliv. 2001;8:143–147.

    Article  CAS  Google Scholar 

  12. Farr SJ, Kellaway IW, Carman-Meakin B. Assessing the potential of aerosol generated liposomes from pressurized pack formulations.J Control Release. 1987;5:119–127.

    Article  CAS  Google Scholar 

  13. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulizers for pulmonary drug delivery.Int J Pharm. 1996;130:1–11.

    Article  Google Scholar 

  14. Davidson IG, Langner EJ, Plowman SV, Blair JA. Release mechanism of insulin encapsulated in trehalose ester derivative microparticles delivered via inhalation.Int J Pharm. 2003;254:211–222.

    Article  CAS  Google Scholar 

  15. Alcock R, Blair JA, O'Mahony DJ, Raoof A, Quirk AV. Modifying the release of leuprolide from spray dried OED microparticles.J Control Release. 2002;82:429–440.

    Article  CAS  Google Scholar 

  16. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.J Control Release. 2004;96:411–423.

    Article  CAS  Google Scholar 

  17. Surendrakumar K, Martyn GP, Hodgers EC, Jansen M, Blair JA. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs.J Control Release. 2003;91:385–394.

    Article  CAS  Google Scholar 

  18. Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.AAPS PharmSciTech. 2002;3:E28.

    Article  Google Scholar 

  19. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection.Biomaterials. 2002;23:4425–4433.

    Article  CAS  Google Scholar 

  20. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.Int J Pharm. 2001;223:15–27.

    Article  CAS  Google Scholar 

  21. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization.AAPS PharmSciTech. 2001;2:E25.

    Article  Google Scholar 

  22. Cortesi R, Esposito E, Gambarin S, Telloli P, Menegatti E, Nastruzzi C. Preparation of liposomes by reverse-phase evaporation using alternative organic solvent.J Microencapsul. 1999;16:251–256.

    Article  CAS  Google Scholar 

  23. Rizk M, Younis F. Spectrophotometric assay of certain aminoglycoside antibiotics using chloranil.Anal Lett. 1984;17:1803–1809.

    CAS  Google Scholar 

  24. Carr RL. Evaluating flow properties of solids.Chem Eng. 1965;72:163–168.

    CAS  Google Scholar 

  25. British Pharmacopoeia Commission. Pressurized inhalations: deposition of the emitted dose. In:British Pharmacopoeia, Vol 2. London, UK: Her Majesty's Stationary Office; 1993:A194-A196.

  26. Hino T, Serigano T, Yamamoto H, Takeuchi H, Niwa T, Kawashima Y. Particle design of wogon extract dry powder for inhalation aerosols with granulation method.Int J Pharm. 1998;168:59–68.

    Article  CAS  Google Scholar 

  27. Betageri GV, Jenkins SA, Parsons DL.Liposome Drug Delivery Systems. Lancaster, PA: Technomic Publishing Company, 1993:16–17.

    Google Scholar 

  28. Staniforth JN. Preformulation aspects of dry powder aerosols. In: Byron PR, Dalby RN, Farr SJ, eds.Respiratory Drug Delivery V. Buffalo Grove, IL: Interpharm Press; 1996: 65–73.

    Google Scholar 

  29. Gonda I. Physico-chemical principles in aerosol-delivery. In: Crommelin DJA, Midha KK, eds.Topics in Pharmaceutical Sciences. Stuttgart, Germany: Medipharm Scientific Publishers: 1992: 95–115.

    Google Scholar 

  30. Hickey AJ.Inhalation Aerosols—Physical and Biological Basis for Theerapy. New York, NY: Marcel Dekker Inc; 1996:441–473.

    Google Scholar 

  31. Hamaker HC. London-van der Waals forces attraction between spherical particles.Physica (Utrecht). 1937;4:1058–1072.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, Faculty of Technology and Engineering, M.S. University of Baroda, Kalabhavan, P.O. Box No. 51, 390001, Vadodara, Gujarat, India

    Shrenik P. Shah & Ambikanandan Misra

Authors
  1. Shrenik P. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ambikanandan Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ambikanandan Misra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shah, S.P., Misra, A. Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance. AAPS PharmSciTech 5, 65 (2004). https://doi.org/10.1208/pt050465

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt050465

Keywords

Search

Navigation